A medicine must first be discovered. It must then be manufactured reliably and reach the patients who need it.
India’s debate on regulatory data protection must account for all three.
Regulatory data protection (RDP) can strengthen the commercial incentive to develop medicines. But exclusivity alone cannot create scientific capability, a culture of discovery or disciplined manufacturing.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
